# S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

> **NCT02177695** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 237 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Methotrexate
- **DRUG:** Vinblastine
- **DRUG:** Doxorubicin
- **DRUG:** Filgrastim

## Key facts

- **NCT ID:** NCT02177695
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-28
- **Primary completion:** 2020-02
- **Final completion:** 2022-12-01
- **Target enrollment:** 237 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02177695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02177695, "S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02177695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*